Source: Annual Congress 2012 - Hot topics in respiratory infections
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Lopez-Giraldo, J. Sellarés, C. Lucena, E. Polverino, C. Cilloniz, R. Amaro, M.A. Marcos, J. Mensa, A. Torres (Barcelona, Spain). Long-term use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. Eur Respir J 2012; 40: Suppl. 56, 2815

Member's Comments

No comment yet.

Related content which might interest you: Predictive factors, microbiology and outcome of patients with parapneumonic effusion Source: Eur Respir J 2011; 38: 1173-1179 Year: 2011 Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia Source: Eur Respir J 2011; 37: 36-41 Year: 2011 Systemic corticosteroid for treating severe community-acquired pneumonia Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Efficacy of intrapleural streptokinase use in complicated parapneumonic pleural effusions and empyema Source: Annual Congress 2008 - Pleural effusion Year: 2008 Pleural empyema in acute bacterial pneumonia in children Source: Eur Respir J 2004; 24: Suppl. 48, 715s Year: 2004 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Inhaled colistin in elderly patients with bronchiectasis and chronic bronchial infection with pseudomonas Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012 Bacteriological and clinical correlates of culture-positive parapneumonic community-acquired pleural infection Source: Virtual Congress 2020 – Clinical challenges in pneumonia Year: 2020 Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Inhaled antibiotics in ventilator-associated pneumonia: treatment or prophylaxis? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016 Effect of corticoids on the clinical course and outcome of severe community-acquired pneumonia Source: Annual Congress 2004 - SARS and other lower respiratory tract infections Year: 2004 Late period pulmonary functions of the patients who were treated for parapneumonic effusion and empyema Source: Eur Respir J 2006; 28: Suppl. 50, 488s Year: 2006 Necrotising pneumonia is an increasingly detected complication of pneumonia in children Source: Eur Respir J 2008; 31: 1285-1291 Year: 2008 Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis Source: Eur Respir J, 54 (1) 1801896; 10.1183/13993003.01896-2018 Year: 2019 Low-dose corticosteroids during severe community-acquired pneumonia: end of the story Source: Eur Respir J 2015; 45: 305-307 Year: 2015 Prophylactic antibiotics will affect the occurrence of post-bronchoscopic fever and pneumonia in patient with endobronchial obstructive lesions? Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007 Experience of ozonotherapy in complex chemotherapy of acute nonspecific pleural empyema Source: Annual Congress 2009 - Pleural problems, congenital lesions and novel technical devices Year: 2009 Long-term treatment with low-dose azithromycin reduces cough, sputum production and exacerbations in patients with idiopathic diffuse bronchiectasis Source: Eur Respir J 2004; 24: Suppl. 48, 707s Year: 2004 Lung function of preschoolers with parapneumonic effusions complicating community acquired pneumonia Source: Annual Congress 2011 - Paediatric respiratory infection: signs, symptoms and sequelae Year: 2011